Clinical Trial Update: Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction [Phase 2]

View source ↗

Summary

Phase 2 frontline trial evaluating cladribine/low-dose cytarabine alternating with decitabine versus hypomethylating agents plus venetoclax for acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Cladribine (cladribine)
• Decitabine (Decitabine)
• Hypomethylating agents (HMA)
• Low-dose cytarabine (Cytarabine (low-dose))
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Florida | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: WITHDRAWN